ライフサイエンスコーパス: systolic blood pressure

1 ed triglycerides, and a possible increase in systolic blood pressure.

2 circulating lipoproteins, inflammation, and systolic blood pressure.

3 which had shown individual association with systolic blood pressure.

4 d coffee intake was not associated with mean systolic blood pressure.

5 pituitary-thyroid axes, as well as a rise in systolic blood pressure.

6 cond semester showed significantly increased systolic blood pressure.

7 regression adjusting for age, sex, race, and systolic blood pressure.

8 lure was nonsignificant after adjustment for systolic blood pressure.

9 iants in SNUPN significantly associated with systolic blood pressure.

10 or renal dysfunction but correlated with low systolic blood pressure.

11 rtensive patients, which was correlated with systolic blood pressure.

12 intensive control versus standard control of systolic blood pressure.

13 resistance -0.0412 (95% CI -0.0685--0.0139), systolic blood pressure 0.0455 (95% CI 0.00137-0.0897),

14 d a larger effect on cardiac parameters than systolic blood pressure (0.06</=beta</=0.21) and a simil

15 The correlation was low for systolic blood pressure (0.39; P<0.0001).

16 f 0.72 (95% CI 0.11-1.34; p < 0.02) mm Hg in systolic blood pressure, 0.45 (95% CI 0.06-0.84; p < 0.0

17 score per standardized residual increase in systolic blood pressure: -0.05; 95% confidence interval:

18 sion (OR = 1.6, 95% CI = 1.2-2.3), increased systolic blood pressure (1.2 per 20mmHg, 95% CI = 1.1-1.

19 potassium ratio was directly associated with systolic blood pressure (1.72 mm Hg; 95% CI, 0.76-2.68).

20 gnificant between-group mean differences for systolic blood pressure (-1.26 mm Hg [95% CI, -1.77 to -

21 ed in a factorial design to target levels of systolic blood pressure (130-149mmHg vs <130mmHg; open l

22 re (hazard ratio=0.79 [95% CI: 0.68-0.92] at systolic blood pressure 160 vs 110 mm Hg) but not for di

23 icantly lower adjusted time-weighted average systolic blood pressure (-17 mm Hg; 95% CI, -25 to -8; p

24 Missing data were common for systolic blood pressure (213 [8.8%]), heart rate (223 [9

25 -0.46 percentage points), weight (-2.98 kg), systolic blood pressure (-3.5 mm Hg), and mean daily bol

26 sium excretion was inversely associated with systolic blood pressure (-3.72 mm Hg; 95% CI, -6.01 to -

27 mference (-4.1 cm; 95% CI, -6.0 to -2.3 cm), systolic blood pressure (-4.9 mm Hg; 95% CI, -9.5 to -0.

28 rotein cholesterol (-0.2 mmol/l; p < 0.001), systolic blood pressure (-9.37 mm Hg; p < 0.001), glycos

29 genes were associated with a 23 mm Hg higher systolic blood pressure (95% CI, 12-34; P=5.6*10(-5)) an

30 ays to 4 years), whereas high bodyweight and systolic blood pressure affected older people (aged 60-8

31 oss of 5% or more, and greater reductions in systolic blood pressure (all p</=0.025).

32 pressure and trials with lower mean baseline systolic blood pressure (all ptrend>0.05).

33 % CI, -8.6 to -4.2; 6 studies; I2 = 51%) for systolic blood pressure and -4.0 mm Hg (95% CI, -5.6 to

34 onal hazards models, using the 120-129 mm Hg systolic blood pressure and 70-79 mm Hg diastolic blood

35 ockers was associated with better control of systolic blood pressure and attenuation of decline in bo

36 ge in LV mass was positively associated with systolic blood pressure and body mass index and negative

37 co-primary endpoints were changes in seated systolic blood pressure and HbA1c measured in the full a

38 t for 6 mo had small but significantly lower systolic blood pressure and improved endothelial functio

39 he ularitide group had greater reductions in systolic blood pressure and in levels of N-terminal pro-

40 nfected participants, associations of higher systolic blood pressure and lower high-density lipoprote

41 ract surgery, PEX was associated with higher systolic blood pressure and more frequent ECG abnormalit

42 alysis to understand the indirect effects of systolic blood pressure and serum aldosterone on the rel

43 inear association between lowest prehospital systolic blood pressure and severity-adjusted probabilit

44 sity lipoprotein-cholesterol, triglycerides, systolic blood pressure and the incidence of the metabol

45 regions, United Nations targets for reducing systolic blood pressure and tobacco use have more substa

46 re noted in trials with higher mean baseline systolic blood pressure and trials with lower mean basel

47 pressure, a slowdown in the increase of both systolic blood pressure and waist circumference, and a r

48 ecrease in low and high frequency spectra of systolic blood pressure, and an increase in spontaneous

49 Conclusion LDL cholesterol level, systolic blood pressure, and diabetes were associated wi

50 rdiometabolic risk factors: body mass index, systolic blood pressure, and fasting glucose level.

51 ng, rectal examination findings, heart rate, systolic blood pressure, and haemoglobin concentration s

52 ts for music on pain after surgery, anxiety, systolic blood pressure, and heart rate, when compared w

53 rmediate outcomes of hemoglobin A1c, weight, systolic blood pressure, and heart rate; all-cause morta

54 ng ratings of friendliness, food intake, and systolic blood pressure, and increasing spontaneous repo

55 or duration, sex, waist-to-hip ratio, HbA1c, systolic blood pressure, and lipids in models with backw

56 seline in glycated hemoglobin level, weight, systolic blood pressure, and mean daily bolus dose of in

57 tended to be younger, with a lower EF, lower systolic blood pressure, and more advanced HF symptoms.

58 d genes involved in VSMC contraction, higher systolic blood pressure, and signs of cardiac hypertroph

59 ute cardiovascular risk of 20% or more, mean systolic blood pressure, and the percentage of current s

60 We examined baseline stenosis severity, systolic blood pressure, and translesion pressure gradie

61 llitus, C-reactive protein, body mass index, systolic blood pressure, and type 1 diabetes mellitus.

62 llitus, C-reactive protein, body mass index, systolic blood pressure, and type 1 diabetes mellitus.

63 ype 2 diabetes mellitus, C-reactive protein, systolic blood pressure, and type 1 diabetes mellitus.

64 t values <3 or >/=3 by body region); initial systolic blood pressure; and Glasgow Coma Scale scores.

65 age, HbA1c, DN, diabetes duration, smoking, systolic blood pressure, antihypertensive medication, an

66 Changes in systolic blood pressure are subsequently converted into

67 A key secondary endpoint was change in home systolic blood pressure at 12 and 24 weeks.

68 The primary outcome was change in systolic blood pressure at 12 months from baseline measu

69 in 25-hydroxyvitamin D and change in 24-hour systolic blood pressure at 6 months (Spearman correlatio

70 from baseline in office and 24 h ambulatory systolic blood pressure at 6 months.

71 Hypertension was defined as systolic blood pressure at or above the 95th percentile

72 loss of 5% or more at week 28; and change in systolic blood pressure at week 28.

73 , injury severity score, Glascow Coma Scale, systolic blood pressure, base excess, platelet count, he

74 pressure lowering, including for those with systolic blood pressure below 140 mmHg.

75 plaque index was positively correlated with systolic blood pressure (beta = 0.80 mm(2)/10 mm Hg; P =

76 CI, 2.04-3.13; P = 1.5 x 10-17), as well as systolic blood pressure (beta = 1.65 mm Hg; 95% CI, 0.78

77 ecruited individuals (aged 30-60 years) with systolic blood pressure between 120 and 139 mm Hg, diast

78 ve drugs, followed by the difference in home systolic blood pressure between spironolactone and each

79 dpoints were the difference in averaged home systolic blood pressure between spironolactone and place

80 d (if significant) by the difference in home systolic blood pressure between spironolactone and the a

81 64-year-old women, presenting difference in systolic blood pressure between upper extremities.

82 The modified EFFECT score, including age, systolic blood pressure, blood urea nitrogen, sodium, ce

83 adjustment for age, sex, diabetes diagnosis, systolic blood pressure, BMI, smoking status, estimated

84 The HFpEF-specific model included age, sex, systolic blood pressure, body mass index, antihypertensi

85 asis model assessment of insulin resistance, systolic blood pressure, body mass index, apolipoprotein

86 After additional adjustment for systolic blood pressure, body mass index, high-sensitivi

87 assessed from respiratory rate, heart rate, systolic blood pressure, body temperature, and level of

88 ee panel recommended a therapeutic target of systolic blood pressure (BP) <150 mm Hg in patients >/=6

89 as associated with a significant decrease in systolic blood pressure (BP) indicators.

90 pertension (142 +/- 8 versus 113 +/- 7 mm Hg systolic blood pressure (BP)), and exhibit increased 20-

91 nts with spontaneous acute ICH with elevated systolic blood pressure (BP), randomly assigned to inten

92 cular mismatch, leading to increased central systolic blood pressure (BP).

93 ence interval, 6.8-14.7) and reduced central systolic blood pressure by 11.6 mm Hg (95% confidence in

94 omparison with MESA, HealthLNK overestimated systolic blood pressure by 6.5 mm Hg (95% confidence int

95 The average reduction in home systolic blood pressure by spironolactone was superior t

96 nt human FGF21 (rhFGF21) on the dysregulated systolic blood pressure, cardiac parameters, baroreflex

97 adjusting for age, gender, body mass index, systolic blood pressure, central corneal thickness, and

98 DKO mice displayed lower systolic blood pressure compared with SPAK knockout (SPA

99 At 12 months, the mean adjusted change in systolic blood pressure compared with usual care was -2.

100 risk, management targeting an individualized systolic blood pressure, compared with standard manageme

101 lood pressure, we found a small reduction in systolic blood pressure control compared with usual care

102 ardiovascular disease who received intensive systolic blood-pressure control (target, <120 mm Hg) had

103 In this simulation study, intensive systolic blood-pressure control prevented cardiovascular

104 BMI, systolic blood pressure, coronary artery disease and typ

105 or cognitive ability in youth), BMI, height, systolic blood pressure, coronary artery disease, and ty

106 educational attainment predicted lower BMI, systolic blood pressure, coronary artery disease, type 2

107 amples, circulating ApoE was associated with systolic blood pressure (correlation coefficient 0.08, p

108 After 9 months, systolic blood pressure decreased (intervention, 14.7 mm

109 Over 3 months, systolic blood pressure decreased, and estimated glomeru

110 roup demonstrated a significant reduction in systolic blood pressure (Delta, -16 mm Hg; 95% confidenc

111 redictors included age, sex, height, weight, systolic blood pressure, diabetes mellitus, smoking, bod

112 However, we found no changes in systolic blood pressure, diasatolic blood pressure, or p

113 , rheumatoid arthritis, knee osteoarthritis, systolic blood pressure, diastolic blood pressure, serum

114 ssed the associations between retirement and systolic blood pressure, diastolic blood pressure, waist

115 The mean reduction in home systolic blood pressure during 24 weeks did not differ s

116 2-hour glucose levels, and 2.1-mm Hg higher systolic blood pressure (each P < .001).

117 y alone based on stenosis severity, level of systolic blood pressure elevation, or according to the m

118 iance was performed on the 6-month change in systolic blood pressure, estimating a mean treatment dif

119 Mediation analysis suggested that systolic blood pressure explained 14% and 20% of the ind

120 body mass index, heart rate, smoking status, systolic blood pressure, fasting glucose, total choleste

121 our top finding (a 0.04 increase in mmHg of systolic blood pressure for 1 standard deviation increas

122 fference in the change in daytime ambulatory systolic blood pressure from baseline to 6 months betwee

123 nterventions: Treatment of hypertension to a systolic blood pressure goal of 120 mm Hg (intensive man

124 atter hyperintensity among participants with systolic blood pressure greater than 140 mm Hg (beta [SE

125 iated with incident hypertension (defined as systolic blood pressure >/=140 mm Hg, diastolic blood pr

126 Hypertension was defined as systolic blood pressure >/=140 mmHg, diastolic blood pre

127 e adults with resistant hypertension (office systolic blood pressure >/=160 mm Hg despite taking at l

128 pants in the subgroup for the upper third of systolic blood pressure (>143.5 mm Hg) who were in the a

129 sly, an inverse association was observed for systolic blood pressure (hazard ratio=0.79 [95% CI: 0.68

130 nal effects of traffic-related pollutants on systolic blood pressure, heart rate variability, correct

131 or diuretic response was associated with low systolic blood pressure, high blood urea nitrogen, and h

132 ble predictors of T2MI were older age, lower systolic blood pressure, history of coronary artery dise

133 eristics following stratification, including systolic blood pressure, history of diabetes mellitus or

134 ortality were obstructive CAD, age, baseline systolic blood pressure, history of diabetes mellitus, h

135 adjusting for age, race, body surface area, systolic blood pressure, history of hypertension, curren

136 tive of lipid or smoking status, and lowered systolic blood pressure in both normolipidemic and hyper

137 t daytime and night-time with less effect on systolic blood pressure in CHF rats.

138 Higher maternal systolic blood pressure in late pregnancy, but not in mi

139 inhibition of RORgammat by digoxin decreased systolic blood pressure in SHRs.

140 nsin-aldosterone system genes associate with systolic blood pressure individually in both sexes, indi

141 Importance: The Systolic Blood Pressure Intervention Trial (SPRINT) demo

142 one of five Clinical Center Networks of the Systolic Blood Pressure Intervention Trial (SPRINT) prov

143 mm Hg in older adults, whereas data from the Systolic Blood Pressure Intervention Trial (SPRINT) sugg

144 We used the Systolic Blood Pressure Intervention Trial (SPRINT) to e

145 In the Systolic Blood Pressure Intervention Trial (SPRINT), adu

146 ed 75 years or older who participated in the Systolic Blood Pressure Intervention Trial (SPRINT).

147 The previously published results of the Systolic Blood Pressure Intervention Trial showed that a

148 SPRINT (Systolic Blood Pressure Intervention Trial) demonstrated

149 nd 19.5% (95% CI, 18.5-20.5) met the SPRINT (Systolic Blood Pressure Intervention Trial) eligibility

150 treatment goal is in question, with SPRINT (Systolic Blood Pressure Intervention Trial) suggesting b

151 he primary end point considering the SPRINT (Systolic Blood Pressure Intervention Trial) target reach

152 SPRINT (Systolic Blood Pressure Intervention Trial) was a random

153 In SPRINT (Systolic Blood Pressure Intervention Trial), a systolic

154 In SPRINT (Systolic Blood Pressure Intervention Trial), patients wi

155 HF) was a frequent common outcome in SPRINT (Systolic Blood Pressure Intervention Trial).

156 Subgroup analyses of SPRINT (Systolic Blood Pressure Intervention Trial).

157 no diabetes mellitus from the SPRINT trial (Systolic Blood Pressure Intervention Trial): 4086 random

158 mes in participants with baseline CKD in the Systolic Blood Pressure Intervention Trial.

159 SGLT2 inhibition caused marked decreases in systolic blood pressure, kidney weight/body weight ratio

160 ment for age, sex, heart rate, hypertension, systolic blood pressure, left ventricular ejection fract

161 Factors associated with early death: Systolic blood pressure less than 90 (p = 0.002) and Cha

162 Subjects with systolic blood pressure less than 90 and Charlson Comorb

163 met one of the following shock criteria: 1) systolic blood pressure less than 90 mm Hg after at leas

164 inflammatory response syndrome criteria, and systolic blood pressure less than 90 mm Hg after fluid r

165 luids, 2) new vasopressor requirement, or 3) systolic blood pressure less than 90 mm Hg and IV fluids

166 auma admitted within 12 hours of injury with systolic blood pressure less than 90 mm Hg or base defic

167 gan dysfunction, endotracheal intubation, or systolic blood pressure less than or equal to 90 mm Hg o

168 trong support for lowering blood pressure to systolic blood pressures less than 130 mm Hg and providi

169 body mass index, smoking, physical activity, systolic blood pressure, lipid profile, retinopathy, est

170 model included age, sex, diabetes duration, systolic blood pressure, low-density lipoprotein cholest

171 alyses to the estimated risk for targets for systolic blood pressure, low-density lipoprotein cholest

172 ng had a clear benefit even in patients with systolic blood pressure lower than 140 mm Hg.

173 In multivariable models, lower systolic blood pressure, lower estimated glomerular filt

174 lder, had longer hemodialysis vintage, lower systolic blood pressure, lower ultrafiltration rates, hi

175 14, respiratory rate >/= 22 breaths/min, or systolic blood pressure </= 100 mm Hg); and 3) revised e

176 lycosylated hemoglobin (HbA1c) </= 6.5%, and systolic blood pressure </= 140 mmHg.

177 response syndrome criteria) and hypotension (systolic blood pressure </=90 mm Hg or mean arterial pre

178 eter blood withdrawal to achieve a sustained systolic blood pressure <10 mmHg, cardiac arrest.

179 Severe CS was defined as systolic blood pressure <90 mm Hg or the need for inotro

180 black and Hispanic race/ethnicity, change in systolic blood pressure, LV mass and DeltaLV mass, N-ter

181 ant clinical outcomes were improved, such as systolic blood pressure [MD: -2.97 mm Hg (95% CI: -5.72,

182 The intervention did not affect change in systolic blood pressure (mean net change -0.37 mm Hg [95

183 directed hemodynamic resuscitation targeting systolic blood pressure of 100 mm Hg and coronary perfus

184 e: titration of chest compression depth to a systolic blood pressure of 100 mm Hg and vasopressor dos

185 of 22/min or greater, altered mentation, or systolic blood pressure of 100 mm Hg or less.

186 risk patients with hypertension, targeting a systolic blood pressure of 120 mm Hg reduces cardiovascu

187 (25-hydroxyvitamin D levels </=25 ng/mL) and systolic blood pressure of 120 to 159 mm Hg.

188 We randomly assigned 9361 persons with a systolic blood pressure of 130 mm Hg or higher and an in

189 ood pressure of 140 mm Hg or higher and home systolic blood pressure of 130 mmHg or higher on permitt

190 Eligible patients had baseline office systolic blood pressure of 140 mm Hg or higher and avera

191 e patients were aged 18-80 years; had clinic systolic blood pressure of 140 mm Hg or higher and home

192 r a median follow-up of 5.0 years, increased systolic blood pressure of 140 mm Hg or more and diastol

193 ong high-risk persons and among those with a systolic blood pressure of 160 mm Hg or higher, but its

194 this population, we defined hypertension as systolic blood pressure of at least 140 mm Hg, or diasto

195 er among those who were assigned to a target systolic blood pressure of less than 120 mm Hg (intensiv

196 tery disease from routine clinical practice, systolic blood pressure of less than 120 mm Hg and diast

197 Systolic blood pressure of less than 120 mm Hg was also

198 lar events but without diabetes, targeting a systolic blood pressure of less than 120 mm Hg, as compa

199 ceived intensive treatment, which targeted a systolic blood pressure of less than 120 mm Hg, were sim

200 ransient ischemic attack to achieve a target systolic blood pressure of less than 140 mm Hg to reduce

201 dividualized assessment, to achieve a target systolic blood pressure of less than 140 mm Hg to reduce

202 ly at or above 150 mm Hg to achieve a target systolic blood pressure of less than 150 mm Hg to reduce

203 the knee or elbow or (2) shock defined as a systolic blood pressure of less than 90 mm Hg or a heart

204 R: 2.18; 95% CI: 1.58, 3.02), new-onset high systolic blood pressure (OR: 1.34; 95% CI: 1.05, 1.70),

205 ted with new-onset overweight, obesity, high systolic blood pressure, or high diastolic blood pressur

206 g association with diastolic blood pressure, systolic blood pressure, or hypertension.

207 compared with the HabDiet, resulted in lower systolic blood pressure (P-diet x time interaction = 0.0

208 rongest predictors showed LASac (P=0.02) and systolic blood pressure (P=0.01) were independently asso

209 (95% CI: 0.02, 0.29; p = 0.022) increase in systolic blood pressure per month and a 0.14-mmHg (95% C

210 atment in adults aged 60 years or older with systolic blood pressure persistently at or above 150 mm

211 nor age at donation, sex, race, preoperative systolic blood pressure, preoperative eGFR, and time sin

212 Age, heart rate, systolic blood pressure, presentation after cardiac arre

213 Heart rate, systolic blood pressure, rate x pressure product, and re

214 Mean office systolic blood pressure reduced by 26.9 (SD 23.9) mm Hg

215 inverse genetic correlations between BW and systolic blood pressure (Rg = -0.22, P = 5.5 x 10(-13)),

216 igh-density lipoprotein (rG=-0.48, P=0.005), systolic blood pressure (rG=0.44, P=0.02), and triglycer

217 history of cardiovascular disease and normal systolic blood pressure (SBP < 130 mmHg).

218 Reduction in systolic blood pressure (SBP reduction) during the treat

219 Fifteen men with early hypertension [systolic blood pressure (SBP) >/=130 mm Hg, diastolic bl

220 ated systolic hypertension (ISH), defined as systolic blood pressure (SBP) >/=140 mm Hg and diastolic

221 6.9% = 1.33, OR7-7.9% = 1.86, OR8%+ = 3.22), systolic blood pressure (SBP) (ORper 10mmHg+ = 1.19), an

222 Baseline systolic blood pressure (SBP) 140 mm Hg or higher was as

223 e aimed to test the hypothesis that elevated systolic blood pressure (SBP) across its usual spectrum

224 were associated under an additive model with systolic blood pressure (SBP) and age at diagnosis of hy

225 ement of Aortic Transcatheter Valve) who had systolic blood pressure (SBP) and an echocardiogram obta

226 mference (WC), waist-to-height ratio (WHtR), systolic blood pressure (SBP) and diastolic blood pressu

227 Circadian misalignment increased 24-h systolic blood pressure (SBP) and diastolic blood pressu

228 action; however, high cumulative exposure to systolic blood pressure (SBP) and diastolic blood pressu

229 cemic index (GI) and glycemic load (GL) with systolic blood pressure (SBP) and diastolic blood pressu

230 rom baseline to the end of the trial in both systolic blood pressure (SBP) and diastolic blood pressu

231 dex (BMI), through other risks, such as high systolic blood pressure (SBP) and high total cholesterol

232 etween greater visit-to-visit variability in systolic blood pressure (SBP) and various outcomes.

233 xperiencing longer periods of critically low systolic blood pressure (SBP) and/or mean arterial press

234 odium-DASH vs. high sodium-control diets) on systolic blood pressure (SBP) by baseline BP.

235 profiling was determined by flow cytometry, systolic blood pressure (SBP) by telemetry, and mesenter

236 he LME to estimate genetic associations with systolic blood pressure (SBP) change trajectories identi

237 onitoring was associated with reduced clinic systolic blood pressure (sBP) compared to usual care at

238 anol users and control subjects (P = 0.040); systolic blood pressure (SBP) did not differ (P = 0.86).

239 stolic Blood Pressure Intervention Trial), a systolic blood pressure (SBP) goal of <120 mm Hg resulte

240 27% reduction in all-cause mortality with a systolic blood pressure (SBP) goal of <120 versus <140 m

241 Recent guidelines recommend a systolic blood pressure (SBP) goal of less than 150 mm H

242 The appropriate treatment target for systolic blood pressure (SBP) in older patients with hyp

243 glycerides (TGs), body mass index (BMI), and systolic blood pressure (SBP) in the Northern Finland Bi

244 servational studies have shown that elevated systolic blood pressure (SBP) is associated with future

245 the potential benefits or risks of intensive systolic blood pressure (SBP) lowering are unclear.

246 chronic kidney disease (CKD) with intensive systolic blood pressure (SBP) lowering is unclear.

247 Patients with an office systolic blood pressure (SBP) of 150 mm Hg or greater an

248 OH was defined as a >/=20 mm Hg drop in systolic blood pressure (SBP) or >/=10 mm Hg drop in dia

249 SPRINT) demonstrated the benefit of lowering systolic blood pressure (SBP) to 120 mm Hg, yet other tr

250 ional Committee (JNC-8) recommended treating systolic blood pressure (SBP) to a target below 150 mm H

251 The optimal systolic blood pressure (SBP) treatment goal is in quest

252 vascular disease (ASCVD) risk to personalize systolic blood pressure (SBP) treatment goals is a topic

253 Low systolic blood pressure (SBP) values are associated with

254 ucose levels, histological deterioration and systolic blood pressure (SBP) with decreased urinary cat

255 zed management strategy aimed at achieving a systolic blood pressure (SBP) within 10% of the referenc

256 (sICAM-1), soluble P-selectin (sP-selectin), systolic blood pressure (SBP), and diastolic blood press

257 The causal relationship between systolic blood pressure (SBP), calf electromyography (EM

258 In secondary analyses at the age of 7 y, systolic blood pressure (SBP), diastolic blood pressure

259 associated with older age, male sex, higher systolic blood pressure (SBP), faster heart rate, greate

260 Systolic blood pressure (SBP), heart rate (HR), patholog

261 For systolic blood pressure (SBP), nickel (Ni) and sodium (N

262 ion of FR167653, p38 MAPK inhibitor, reduced systolic blood pressure (SBP), urinary albumin excretion

263 ents with acute spontaneous ICH and elevated systolic blood pressure (SBP)-randomly assigned to inten

264 independently of cardiac biomarkers and low systolic blood pressure (SBP).

265 nization therapy (CRT) was shown to increase systolic blood pressure (SBP).

266 Significant reductions in 24-h BP [for systolic blood pressure (SBP): -3.9 mm Hg; for diastolic

267 ol (NSNPs = 57), triglycerides (NSNPs = 39), systolic blood pressure (SBP, NSNPs = 24), smoking initi

268 For systolic blood pressure, self-reported alcohol consumpti

269 Higher systolic blood pressure showed an inverse association wi

270 Every 10 mm Hg reduction in systolic blood pressure significantly reduced the risk o

271 We assessed the following 4 risk factors: systolic blood pressure, smoking status, diabetes, and t

272 h interleukin-6 (Spearman r=0.33, P<0.0001), systolic blood pressure (Spearman r=0.28, P<0.0001), bod

273 uminuria, although they exhibited comparable systolic blood pressure, sympathetic nerve activity and

274 diovascular risk, but without diabetes, to a systolic blood-pressure target of less than 120 mm Hg (i

275 ned 9361 participants with hypertension to a systolic blood-pressure target of less than 120 mm Hg or

276 poor neighborhoods was associated with lower systolic blood pressure than was consistent residence in

277 s. 32.9 +/- 16.6 ms/mmHg, P < 0.005), 2) the systolic blood pressure threshold for baroreflex activat

278 ital traumatic brain injury guidelines use a systolic blood pressure threshold of less than 90 mm Hg

279 The most appropriate targets for systolic blood pressure to reduce cardiovascular morbidi

280 14) with more than 1 million measurements of systolic blood pressure, total cholesterol, and high-den

281 icantly associated with BMI, hemoglobin A1c, systolic blood pressure, total cholesterol, LDL choleste

282 hypertension were modeled as a reduction in systolic blood pressure; treatment of isolated diastolic

283 age, male sex, black race, current smoking, systolic blood pressure, use of antihypertensive medicat

284 high-density lipoprotein cholesterol level, systolic blood pressure, use of antihypertensive treatme

285 e analyses adjusting for age and sex, higher systolic blood pressure values were noted for the PEX gr

286 Systolic blood pressure variability (SBPV) was measured

287 Systolic blood pressure, waist circumference (WC), and f

288 At 1 year, the mean systolic blood pressure was 121.4 mm Hg in the intensive

289 itional antihypertensive medication, and the systolic blood pressure was 14.8 mm Hg (95% confidence i

290 secondary analyses, adjusted mean ambulatory systolic blood pressure was 3.06 mmHg lower (95% CI 0.56

291 the dual-placebo group, and the decrease in systolic blood pressure was 6.2 mm Hg greater with combi

292 en-patient variability of daytime ambulatory systolic blood pressure was greater for nonadherent than

293 After 6 mmol of KNO3, systolic blood pressure was reduced by a maximum of 17.9

294 Seated systolic blood pressure was significantly reduced in the

295 contrast, lower resting heart rate and lower systolic blood pressure were associated with substance u

296 ortional risk reductions (per 10 mm Hg lower systolic blood pressure) were noted in trials with highe

297 TR1) were individually associated with lower systolic blood pressure with significant (P<0.00076) eff

298 METHODS AND We tested association of systolic blood pressure with single-nucleotide polymorph

299 re were significant and similar decreases in systolic blood pressure with spironolactone and HCTZ but

300 1.4]; 22 trials, 2721 participants), diurnal systolic blood pressure (WMD, -2.4 points [95% CI, -3.9